Ceapro (CZO.V) Stock Price
Ceapro Price
Revenue has compounded at 8.8% per year over the past 19 years to 9.63 M CAD. Earnings per share have grown at 16.6% per year over the last 12 years. Ceapro's net margin stands at -48.9%, down from -8.8% several years earlier.
Ceapro stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Ceapro business model & stock analysis
Frequently asked questions about Ceapro
The business model of Ceapro Inc revolves around the development and commercialization of innovative natural products derived from oats and other plant sources. Ceapro specializes in the extraction and purification of active ingredients for the pharmaceutical, cosmetic, and human health markets. By leveraging its proprietary technologies, Ceapro harnesses the power of nature to create high-value products that provide sustainable and renewable solutions. With a strong focus on research and development, Ceapro aims to deliver unique and effective products for a wide range of applications, catering to the growing demand for natural and environmentally friendly alternatives.
Ceapro Inc is primarily active in the biotechnology industry.
Some major competitors of Ceapro Inc in the market include Active Organics, Ashland LLC, and Croda International.
Ceapro Inc. is a Canadian biotechnology company that specializes in developing and manufacturing innovative extracts and active ingredients derived from natural sources. Established in 1997, Ceapro has a rich history of over two decades in the biopharmaceutical industry. The company focuses on utilizing its patented technology to transform renewable resources into high-value functional products. Ceapro's expertise lies in the production of unique biopolymers, such as beta glucan, as well as other innovative solutions for human and animal health. With a commitment to sustainability and scientific excellence, Ceapro continues to thrive as a leader in the biotechnology sector.
Ceapro Inc has achieved significant milestones throughout its journey. The company successfully developed and commercialized its flagship product, Avenanthramides, which has gained recognition for its numerous health benefits. Additionally, Ceapro Inc has built a strong research and development platform, leading to the creation of innovative products derived from natural sources. The company has also collaborated with renowned academic institutions and established partnerships with leading players in the industry, enhancing its global presence. With a dedicated focus on sustainability and continuous growth, Ceapro Inc remains committed to delivering high-quality, nature-based solutions to improve the health and well-being of consumers.
Ceapro Inc is primarily present in Canada and the United States.
Ceapro Inc represents values of excellence, innovation, and sustainability. As a biotechnology company, Ceapro is dedicated to developing and commercializing active ingredients derived from natural resources for personal care, cosmetics, and pharmaceutical industries. The corporate philosophy of Ceapro emphasizes a commitment to cutting-edge research, high-quality products, and environmental responsibility. By combining advanced technology with a deep understanding of natural materials, Ceapro aims to provide effective and sustainable solutions to its clients. With its focus on innovation and dedication to eco-friendly practices, Ceapro Inc stands as a leading player in the biotechnology industry.
9 analysts currently rate the Ceapro stock: 8 recommend buying, 1 holding and 0 selling.
The Ceapro share (CZO.V) is listed on 2 stock exchanges, including: Toronto (CZO.V).
Ceapro Inc is a Canadian company specialized in the development and manufacturing of natural health and beauty products from plant and marine sources. The company is headquartered in Edmonton, Alberta, and has state-of-the-art production facilities, research and development departments, as well as sales and marketing teams in North America, Europe, and Asia. Ceapro offers a wide range of products that are highly regarded worldwide for their high quality and effectiveness. These include products from five different business units: 1. Health and Wellness: This business unit includes products such as Beta-Glucan, a natural immune stimulant used mainly in the pharmaceutical and food industry. Ceapro also produces Chitosan, a fiber derived from crabs and shrimps, used in wound healing, cosmetics, and dietary supplements. 2. Cosmeceuticals: Under this unit, Ceapro offers skincare products based on natural ingredients such as Beta-Glucan and Avenanthramid. The company provides an anti-aging product line, such as HyaClear, which is based on Hyaluronic Acid. 3. Functional Food: Ceapro offers natural food additives under this unit that provide health benefits, such as Beta-Glucan or plant fibers that support digestion. 4. Veterinary Health: Ceapro also produces a range of veterinary products, including Beta-Glucan-based products to strengthen pets' immune systems and Chitosan-based wound care products. 5. Active Ingredients: Under this business unit, Ceapro supplies natural active ingredients to the pharmaceutical and cosmetics industries, which can be used in prescription products, over-the-counter medications, and cosmetics. Ceapro employs an integrated approach that extends from research and development to the production process to ensure high quality and effectiveness of its products. The company relies on unique and patented processes to extract active ingredients from plant and marine sources and consistently invests in research and development to develop innovative products that meet market needs. The company is led by an experienced management team composed of seasoned scientists and business professionals who share Ceapro's vision of improving people's lives by offering natural products of the highest quality. To effectively market its products, Ceapro relies on a global distribution strategy that includes a comprehensive presence in North America, Europe, and Asia. The company maintains strong partnerships with several companies in various industries, including animal health, food, pharmaceutical, and cosmetics industries. Conclusion Ceapro Inc is a leading company in the development and production of natural health and beauty products from plant and marine sources. The company specializes in five business units that encompass a wide range of products, from food additives to animal health products. Ceapro employs an integrated research and development strategy to develop innovative products that meet market needs. The company has a broad global distribution strategy and is dedicated to offering natural products of the highest quality to improve people's lives.
The revenue cannot currently be calculated for Ceapro.
The profit cannot currently be calculated for Ceapro.
The P/E ratio cannot be calculated for Ceapro at the moment.
The P/S cannot be calculated for Ceapro currently.
The Eulerpool Quality Score for Ceapro is 2/10.
The ISIN of Ceapro is CA1499071076. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Ceapro is 931278. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Ceapro is CZO.V. The ticker symbol is used to trade Ceapro shares on the stock exchange.
Ceapro stock
Ceapro Peer Group
Ceapro Ticker
Ceapro FIGI
All fundamentals and in-depth analysis of Ceapro
Our stock analysis for Ceapro stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ceapro. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.